ecancermedicalscience

Review

Infracentimetric HER-2 positive breast tumours—review of the literature

18 Nov 2015
Danilo da Fonseca Reis Silva, Joana M Ribeiro

Breast cancer is the most common malignant neoplasm in the world among women. As a result of the dissemination of population screening programmes, about half of non-metastatic breast cancers are now diagnosed at stage I. 10–15% of T1abN0 tumours over-express human epidermal growth factor (HER-2). These tumours have a globally excellent prognosis, however, treatment with chemotherapy and/or targeted therapy may further improve outcomes in selected cases. In this article, we will review studies with information on prognosis and benefit of adjuvant therapy for T1abN0 HER-2 breast cancer.

Related Articles

Jessica O Esangbedo, Rachael O Oduyemi, Damilare Aduroja, Yetunde O Tola, Olajumoke Dele-Alonge, Emmanuel O Adesuyi, Michael O Ajiboye, Oluwadamilare Akingbade
Sushmita Rath, Mehak Trikha, Laboni Sarkar, Kunal Jobanputra, Akash Pawar, Revathy Krishnamurthy, Ayushi Sahay, Palak, Purvi Thakkar, Sneha Shah, Venkatesh Kapu, Anbarasan Sekar, Prabhat Bhargava, Seema Gulia, Rima Pathak, Tabassum Wadasadawala, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta, Jyoti Bajpai
Francisca Quintanilla, Álvaro Torres, Monserrat Villar, Catalina Muñoz, José Lizama, Bárbara Mena
Association of Medical and Pediatric Oncologists of Kerala (AMPOK)
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston